Research report: Revisiting Ehrlich carcinoma in the era of precision oncology: bridging classical models with modern systems biology

A 2026 review argues that Ehrlich carcinoma and its ascitic form, Ehrlich ascites carcinoma, could acquire new value in precision oncology if researchers combine the established murine model with single-cell profiling, spatial transcriptomics, multi-omics, CRISPR experiments and focused analysis of the RNA-induced silencing complex. The authors present Ehrlich carcinoma as a complementary platform for studying aggressive tumor biology in an immunocompetent host, rather than as a replacement for organoids, patient-derived xenografts or genetically engineered mouse models. The proposal is a research framework, not a new intervention: the review synthesizes existing evidence and identifies untested directions, including whether altered post-transcriptional regulation helps shape tumor growth, immune responses and treatment sensitivity.

Ehrlich carcinoma is among cancer research’s oldest and most widely used experimental tumor models. It was initially isolated from murine mammary tissue in work associated with Paul Ehrlich and later developed into an ascitic form. Its practical advantages include rapid tumor establishment after subcutaneous or intraperitoneal inoculation, straightforward transplantation, reproducibility under established conditions and growth in immunocompetent hosts without extensive genetic manipulation.

Solid tumors provide a localized mass for studying angiogenesis and growth, whereas the ascitic form grows in the peritoneal cavity and permits examination of disseminated tumor cells and organism-level interactions. These properties support investigation of tumor growth, immune dysregulation, metabolic remodeling, treatment response and cancer-associated complications, but the model does not reproduce the full biology of human breast cancer. As tumor burden increases, experimental animals can develop cachexia, anemia and hepatic or renal dysfunction, with multi-organ failure as a systemic consequence.

Ehrlich carcinoma therefore offers a way to examine how malignancy changes whole-host physiology rather than only the behavior of cultured tumor cells. The review describes applications in anticancer-agent testing, immunomodulator research and metabolic-inhibitor studies. It also identifies features of aggressive tumor biology that make the model relevant to angiogenesis, inflammation, oxidative stress, therapeutic resistance and immune–metabolic remodeling.

Those features must be interpreted carefully: the experimental tumor is transplantable and relatively undifferentiated, and ascitic Ehrlich carcinoma should not be treated as a direct representation of breast cancer peritoneal metastasis. Neither solid nor ascitic disease captures the full architecture, cellular diversity, patient-specific genetics or endocrine environment of human tumors. Most historical EC/EAC research has focused on tumor inhibition, drug screening, individual biochemical markers, signaling pathways and early phenotypic outcomes.

Established areas of investigation include PI3K/AKT/mTOR, NF-κB, apoptosis, hypoxia-associated angiogenesis, inflammatory mediators and pathways associated with metabolic plasticity and drug resistance. The model has consequently supported studies of targeted therapeutics, nanomedicines, gene manipulation and therapeutic combinations. However, the review notes that many experiments cover short periods and emphasize early tumor inhibition rather than dormancy, immune adaptation, relapse, acquired resistance or delayed organ toxicity.

Variability in host strain, inoculation dose, tumor form and outcome measurement also weakens cross-study comparability. The authors therefore recommend longer studies with serial sampling, survival-based endpoints and common reporting standards for tumor burden, immune biomarkers, metabolic measures, organ toxicity and survival. The review’s most specific proposal centers on RNA-induced silencing complex, or RISC, which links microRNA expression to repression of target transcripts.

Mature microRNAs are processed by Dicer and loaded into Argonaute-containing RISC complexes, with AGO2 occupying the pathway’s functional core. Individual microRNAs have already been studied in Ehrlich carcinoma. Reported work has linked miR-125a-5p with reduced STAT3 activation and enhanced doxorubicin response following thymoquinone treatment, while miR-191-5p and miR-543 have been examined in relation to metabolic and inflammatory responses.

These findings support an involvement for small-RNA regulation, but they do not define the coordinated relationship among microRNA abundance, Dicer, Argonaute proteins, target repression and tumor phenotype. The abundance of one microRNA alone consequently cannot establish whether the silencing machinery is functionally active or whether an observed transcript change is caused by microRNA-mediated repression. A testable workflow proposed in the review would begin with comparative microRNA profiling of Ehrlich carcinoma tissue and appropriate controls, alongside measurement of AGO2, Dicer and related components at RNA and protein levels.

These data could be integrated with RNA sequencing or targeted transcriptomics to nominate candidate regulatory networks. Researchers could then use gain- and loss-of-function experiments to test selected interactions and assess proliferation, migration, invasion, apoptosis and treatment response. The central hypothesis is that altered RISC activity contributes to aggressive phenotypes by reshaping post-transcriptional control of genes involved in growth, apoptosis, epithelial–mesenchymal transition, inflammation and therapy response.

That hypothesis remains to be established. A combined small-RNA, transcriptomic, protein and functional approach would help distinguish changes in microRNA expression from changes in the activity of the silencing machinery itself. Integrated multi-omics could broaden the analysis beyond individual pathways.

The review proposes combining transcriptomic, proteomic, metabolomic, lipidomic and small-RNA measurements to identify coordinated molecular programs associated with progression, treatment response and host toxicity. Such an EC/EAC atlas has not yet been assembled, and the ascitic and solid forms have not been comprehensively compared through such an integrated framework. Coordinated profiling could reveal redundancy, immunometabolic communication and adaptive states that are difficult to infer from one molecular layer.

Epigenetic analysis is an additional priority. DNA methylation, histone modification, chromatin accessibility and higher-order chromatin structure have received comparatively little attention in this model, leaving poorly characterized the regulatory processes associated with phenotypic plasticity, immune suppression and resistance. Epigenomic mapping could therefore test whether reversible chromatin states contribute to transitions among proliferative, invasive, stem-like or drug-tolerant phenotypes.

Single-cell RNA sequencing and spatial transcriptomics could extend the analysis from bulk tissue to the cellular ecosystem. Conventional assays can conceal malignant subclones, distinct immune-cell states and local signaling niches, while ascitic tumors lack the spatial organization characteristic of solid human malignancies. High-resolution profiling could identify where regulatory signals originate and clarify relationships among tumor cells, infiltrating immune cells and stromal compartments.

Functional genomics would add causal tests to this descriptive work. Ehrlich carcinoma has been studied less with CRISPR-based tools than with pharmacological inhibitors, antioxidants or dietary interventions that can act on several targets at once. Stable knockouts, inducible knockdowns, knock-in reporters and barcoded populations could test whether specific genes contribute to growth, immune regulation, resistance or host toxicity.

The review also proposes systematic profiling of PD-1, PD-L1, CTLA-4, LAG-3, TIM-3 and TIGIT, whose expression dynamics, cellular origins and functional relevance remain incompletely characterized in the model. More exploratory directions include tumor–microbiome interactions, dynamic metabolic analysis, neuro-tumoral signaling and circadian regulation. Ehrlich carcinoma’s rapid proliferation, systemic inflammation, cachexia and immune–metabolic remodeling make these subjects accessible, but the review treats them as proposed areas for future work rather than established findings in EC/EAC.

Isotope tracing and flux analysis could examine how tumor and host cells reallocate nutrients during hypoxia or treatment, providing more information than static measurements of glucose uptake, lactate, lipid peroxidation or antioxidant enzymes. Microbiome studies could test whether the tumor alters gut microbial communities or whether microbial metabolites influence systemic inflammation and treatment response. Because the model induces endocrine and stress responses, neural and neuroimmune signaling may also be examined experimentally.

Manipulating light–dark cycles, feeding times and treatment schedules could support chronobiology studies of tumor growth, immune activity and therapeutic sensitivity, although evidence specific to Ehrlich carcinoma remains limited. The review concludes that modernizing Ehrlich carcinoma does not require the model to become a substitute for clinically representative systems. Organoids and patient-derived xenografts can retain patient-specific tumor features; genetically engineered mouse models can define genetic drivers; and EC/EAC provides a comparatively accessible, immunocompetent environment in which growth, immunity, metabolism and treatment effects can be observed together.

A practical discovery-to-validation pathway would move from multi-omics and small-RNA profiling to candidate RISC-regulated networks, then to CRISPR or pharmacological perturbation, assessment of tumor, immune and treatment phenotypes, and validation in breast cancer cell systems, organoids, patient-derived xenografts or other appropriate models. Important limits remain: species-specific immune and stromal differences, limited heterogeneity, passage history, the ascitic phenotype, experimentally introduced established cells and the inability to model early carcinogenesis or patient-specific responses. The value of EC/EAC therefore lies in identifying mechanisms robust enough to justify validation across complementary models, not in treating its findings as direct evidence of human breast cancer biology.

Subject of Research: Review of methods for modernizing Ehrlich carcinoma as a complementary in vivo model of tumor and host biology

Article Title: Revisiting Ehrlich carcinoma in the era of precision oncology: bridging classical models with modern systems biology

Article References: Manjunath, V., Nayak, R. R., Bhujanga, A. K., Ramesh, A. M., & Santhekadur, P. K. (2026). Revisiting Ehrlich carcinoma in the era of precision oncology: bridging classical models with modern systems biology. Medical Oncology, 43(11), Article 342. https://doi.org/10.1007/s12032-026-03452-x

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03452-x

Keywords: Ehrlich carcinoma, Ehrlich ascites carcinoma, systems biology, precision oncology, RNA-induced silencing complex, microRNA regulation, multi-omics, single-cell profiling, spatial transcriptomics, CRISPR functional genomics, tumor microenvironment, murine cancer models